Skip to content

Vitrification of Oocytes Matured by CAPA-IVM

Vitrification of In Vitro Matured Oocytes Following the CAPA-IVM Methodology

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06157619
Enrollment
20
Registered
2023-12-06
Start date
2023-12-31
Completion date
2025-03-31
Last updated
2023-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility Preservation

Keywords

In Vitro maturation, Oocyte vitrification, Fertility preservation

Brief summary

It has been reported that the potential of In Vitro matured oocytes might be affected by the vitrification process. In fact, the freezing and thawing procedures routinely used in IVF laboratories, have not yet been adapted to oocytes coming from early antral follicles (normally used for In Vitro Maturation). This study aims to compare 2 existing protocols for the Vitrification of In Vitro matured oocytes.

Detailed description

This is a single-center non-blinded observational study. The proposed study will follow a sibling oocyte design in infertile patients. In Vitro Maturation will be performed by using the Capacitation-IVM (CAPA-IVM) methodology. All cumulus-oocyte complexes (COC) recovered from the patient will be cultured in CAPA medium for 24 hours and then matured for 30 hours (IVM). A minimum of 10 metaphase II (MII) stage oocytes are expected from each CAPA-IVM procedure. After CAPA-IVM culture, the mature oocytes (MII) will be randomly divided (50/50) into two groups to be subjected to the two vitrification protocols. In a second step (next cycle), the oocytes from each group will be thawed and fertilized by Intracytoplasmic sperm injection (ICSI). The derived embryos will be cultured to the blastocyst stage (Day 5/6). The transfer of a single embryo (the one with the best quality) will be carried out. The remaining embryos will be vitrified.

Interventions

PROCEDUREOocyte Vitrification /Warming

In Vitro matured oocytes will be randomly assigned to any of the two Vitrification protocols

Sponsors

Centro de Estudios e Investigaciones en Biología y Medicina Reproductiva
CollaboratorUNKNOWN
Centro de Fertilidad y Reproducción Asistida, Peru
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 37 Years
Healthy volunteers
Yes

Inclusion criteria

Either * Patients with Polycystic ovary morphology: At least 25 follicles (2-9 mm) throughout the ovary and/or increased ovarian volume (\>10ml) (it is enough for 1 ovary to meet these criteria) * Patients with good ovarian reserve: High antral follicle count (AFC): ≥ 20 antral follicles in both ovaries or Anti-müllerian hormone (AMH) value ≥3.5 ng/ml In both cases, without significant uterine or ovarian anomalies

Exclusion criteria

* There are contraindications for the administration of gonadotropins, oral contraceptives and/or other drugs used in the framework of the present study. * Preimplantation Genetic Testing (PGT) Cycles * Oocyte donation cycles * Medical contraindication for pregnancy. * High grade endometriosis (\> grade 2) * Cases with extremely poor sperm

Design outcomes

Primary

MeasureTime frameDescription
Oocyte survival rate6 monthsThe survival rate will be calculated by dividing the number of oocytes that survive freezing/thawing by the number of oocytes originally frozen. Survival rate will be evaluated per patient, per vitrification protocol.

Secondary

MeasureTime frameDescription
Fertilization rate6 monthsThe fertilization rate will be calculated by dividing the number of fertilized oocytes by the number of oocytes injected by ICSI.
Cleavage rate6 monthsThe cleavage rate will be calculated by dividing the number of cleaving embryos by the number of fertilized oocytes.
Rate of Blastocyst formation6 monthsThe rate of blastocyst formation will be calculated by dividing the number of blastocysts by the number of fertilized oocytes.
Oocyte maturation rate6 monthsThe maturation rate will be calculated by dividing the number of oocytes that mature by the number of oocytes originally plated.
Clinical pregnancy rate15 monthsThe clinical pregnancy rate will be calculated by dividing the number of patients with clinical pregnancy by the number of patients that underwent embryo transfer procedures.
Live birth rate15 monthsThe live birth rate will be calculated by dividing the number of patients with a live birth by the number of patients that underwent embryo transfer procedures.
Rate of Good quality blastocysts6 monthsThe rate of good quality blastocysts will be calculated by dividing the number of good quality blastocysts by the number of fertilized oocytes.

Countries

Peru

Contacts

Primary ContactSergio Romero, PhD
sergioromero@cefra.com.pe+51-1-2230363

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026